{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:44:29Z","timestamp":1790520269856,"version":"4.1.0"},"reference-count":82,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T00:00:00Z","timestamp":1592092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Colon cancer is one of the most frequently diagnosed malignancies in adults, considering both its incidence and prevalence. Anatomically, the right colon is considered as being from the cecum to the splenic flexure, and the left colon is from the splenic flexure to the rectum. Sidedness is a surrogate of a wide spectrum of colorectal cancer (CRC) biology features (embryology, microbiome, methylation, microsatellite instability (MSI), BRAF, aging, KRAS, consensus molecular subtypes (CMS), etc.), which result in prognostic factors. Different molecular subtypes have been identified, according to genomic and transcriptomic criteria. A subgroup harboring a BRAF mutation has been described, and represents approximately 10% of the patients diagnosed with colon cancer. This subgroup has morphological, clinical, and therapeutic characteristics that differ substantially from patients who do not carry this genetic alteration. Unfortunately, there is no established standard of care for this particular cohort of patients. This manuscript aims to study the biology of this subgroup of colon cancer, to understand the current approach in clinical research.<\/jats:p>","DOI":"10.3390\/cancers12061571","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T12:16:57Z","timestamp":1592223417000},"page":"1571","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["BRAF Mutated Colorectal Cancer: New Treatment Approaches"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-0598","authenticated-orcid":false,"given":"Javier","family":"Molina-Cerrillo","sequence":"first","affiliation":[{"name":"Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain"},{"name":"CIBERONC, The Ram\u00f3n y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain"},{"name":"Medicine School, Alcal\u00e1 University, 28805 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"San Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pozas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-7236","authenticated-orcid":false,"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain"},{"name":"CIBERONC, The Ram\u00f3n y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain"},{"name":"Medicine School, Alcal\u00e1 University, 28805 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Pozas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-9602","authenticated-orcid":false,"given":"Elisa","family":"Conde","sequence":"additional","affiliation":[{"name":"Biomarkers and Therapeutic Targets Group and Core Facility, The Ram\u00f3n y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rosas","sequence":"additional","affiliation":[{"name":"Pathology department, University Hospital Ramon y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, MD Anderson Cancer Center, 28033 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Laura","family":"Garc\u00eda-Bermejo","sequence":"additional","affiliation":[{"name":"Biomarkers and Therapeutic Targets Group and Core Facility, The Ram\u00f3n y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8140","authenticated-orcid":false,"given":"Alfredo","family":"Carrato","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain"},{"name":"CIBERONC, The Ram\u00f3n y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain"},{"name":"Medicine School, Alcal\u00e1 University, 28805 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,14]]},"reference":[{"key":"ref_1","first-page":"89","article-title":"Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Przeglad Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12094-018-02002-w","article-title":"SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)","volume":"21","author":"Gallego","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","unstructured":"Winawer, S.J. (1992). Management of Gastrointestinal Diseases, Gower Medical Publishing."},{"key":"ref_5","first-page":"4759","article-title":"Colorectal Carcinogenesis: Role of Oxidative Stress and Antioxidants","volume":"37","author":"Carini","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa1100370","article-title":"Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths","volume":"366","author":"Zauber","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"De Palma, F., D\u2019argenio, V., Pol, J., Kroemer, G., Maiuri, M.C., and Salvatore, F. (2019). The molecular hallmarks of the serrated pathway in colorectal cancer. Cancers, 11.","DOI":"10.3390\/cancers11071017"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1158\/0008-5472.CAN-08-1171","article-title":"Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases","volume":"68","author":"Barault","year":"2008","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0168-9525(93)90209-Z","article-title":"The multistep nature of cancer","volume":"9","author":"Vogelstein","year":"1993","journal-title":"Trends Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/\u03b2-Catenin Signaling: Components, Mechanisms, and Diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s12253-011-9409-4","article-title":"Prognostic significance of Wnt-1, \u03b2-catenin and E-cadherin expression in advanced colorectal carcinoma","volume":"17","author":"Stanczak","year":"2011","journal-title":"Pathol. Oncol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1440-1746.2012.07200.x","article-title":"Molecular pathways in colorectal cancer","volume":"27","author":"Biankin","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/gut.2009.206250","article-title":"Colorectal cancer molecular biology moves into clinical practice","volume":"60","author":"Pritchard","year":"2011","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PPO.0b013e318237e408","article-title":"Inherited colorectal cancer syndromes","volume":"17","author":"Kastrinos","year":"2011","journal-title":"Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1056\/NEJMra0804588","article-title":"Molecular origins of cancer: Molecular basis of colorectal cancer","volume":"361","author":"Markowitz","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/ejhg.2015.252","article-title":"Combined mismatch repair and POLE\/POLD1 defects explain unresolved suspected Lynch syndrome cancers","volume":"24","author":"Jansen","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/1096-9896(200103)193:3<283::AID-PATH799>3.0.CO;2-9","article-title":"Serrated route to colorectal cancer: Back street or super highway?","volume":"193","author":"Jass","year":"2001","journal-title":"J. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.gastro.2006.09.018","article-title":"The CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer","volume":"132","author":"Goel","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ncponc0248","article-title":"Serrated adenoma of the colorectum and the DNA-methylator phenotype","volume":"2","author":"Jass","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ogino, S., Kawasaki, T., Kirkner, G.J., Ohnishi, M., and Fuchs, C.S. (2007). 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-72"},{"key":"ref_22","first-page":"120","article-title":"The CpG island methylator phenotype (CIMP) in colorectal cancer","volume":"6","author":"Mojarad","year":"2013","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"18654","DOI":"10.1073\/pnas.0704652104","article-title":"Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer","volume":"104","author":"Shen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-07-1489","article-title":"Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer","volume":"14","author":"French","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-11237-6","article-title":"Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer","volume":"7","author":"Purcell","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.18.02258","article-title":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: Results from CALGB\/SWOG 80405 (Alliance)","volume":"37","author":"Lenz","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamaoncol.2016.2314","article-title":"Clinical outcome from oxaliplatin treatment in stage II\/III colon cancer according to intrinsic subtypes: Secondary analysis of NSABP C-07\/NRG oncology randomized clinical trial","volume":"2","author":"Song","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ijc.31767","article-title":"Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models","volume":"144","author":"Prasetyanti","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/annonc\/mdy410","article-title":"The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: Molecular analysis of the AGITG MAX clinical trial","volume":"29","author":"Mooi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_33","first-page":"105","article-title":"Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications","volume":"3","author":"Thanki","year":"2017","journal-title":"Int. Biol. Biomed. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/annonc\/mdz387","article-title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial","volume":"30","author":"Stintzing","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1042\/bj3510289","article-title":"Meaningful relationships: The regulation of the Ras\/Raf\/MEK\/ERK pathway by protein interactions","volume":"351","author":"Kolch","year":"2000","journal-title":"Biochem. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1758835919856494","DOI":"10.1177\/1758835919856494","article-title":"Molecular targeted therapy of BRAF-mutant colorectal cancer","volume":"11","author":"Ducreux","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.6004\/jnccn.2013.0182","article-title":"Sessile Serrated Polyps: An Important Route to Colorectal Cancer","volume":"11","author":"Kalady","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.onc.1210704","article-title":"BRAF (E600) in benign and malignant human tumours","volume":"27","author":"Michaloglou","year":"2008","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2018.36.15_suppl.3513","article-title":"Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer","volume":"36","author":"Wang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/annonc\/mdw645","article-title":"Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials","volume":"28","author":"Seligmann","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.7150\/jca.3619","article-title":"Rare though not mutually exclusive: A report of three cases of concomitant kras and braf mutation and a review of the literature","volume":"4","author":"Sahin","year":"2013","journal-title":"J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","article-title":"BRAF V600E mutant colorectal cancer subtypes based on gene expression","volume":"23","author":"Barras","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Caputo, F., Santini, C., Bardasi, C., Cerma, K., Casadei-Gardini, A., Spallanzani, A., Andrikou, K., Cascinu, S., and Gelsomino, F. (2019). BRAF-mutated colorectal cancer: Clinical and molecular insights. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215369"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/annonc\/mdv290","article-title":"BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis","volume":"26","author":"Cremolini","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","article-title":"Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","volume":"35","author":"Jones","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"V58","DOI":"10.1093\/annonc\/mdy151.206","article-title":"Clinico-pathological and molecular characterization of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?","volume":"29","author":"Schirripa","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1158\/1078-0432.CCR-19-2004","article-title":"Response to anti-EGFR therapy in patients with BRAF non-V600\u2013mutant metastatic colorectal cancer","volume":"25","author":"Yaeger","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/jnci\/djt173","article-title":"Microsatellite instability and braf mutation testing in colorectal cancer prognostication","volume":"105","author":"Lochhead","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"dju106","DOI":"10.1093\/jnci\/dju106","article-title":"Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG\/Alliance N0147","volume":"106","author":"Gonsalves","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1200\/JCO.2018.36.15_suppl.3597","article-title":"Prognostic impact of BRAF V600E mutation in patients with non-metastatic colorectal cancer with microsatellite instability: A systematic review and meta-analysis","volume":"36","author":"Manthravadi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/bjc.2015.173","article-title":"Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer","volume":"112","author":"Rowland","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","article-title":"Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis","volume":"51","author":"Pietrantonio","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis","volume":"11","author":"Claes","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Martini","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2019.37.15_suppl.3511","article-title":"mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109)","volume":"37","author":"Geissler","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_56","unstructured":"NCCN Clinical Practice Guidelines in Oncology (2020, May 22). Colon Cancer, version 3.2020. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/dji174","article-title":"Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab","volume":"97","author":"Ince","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","article-title":"Mutational Analysis of Patients with Colorectal Cancer in CALGB\/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome","volume":"37","author":"Innocenti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1470-2045(10)70175-3","article-title":"Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: A phase 2 trial","volume":"11","author":"Masi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2013.08.024","article-title":"FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer","volume":"50","author":"Loupakis","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-14-2779","article-title":"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients","volume":"21","author":"Yaeger","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1158\/0008-5472.CAN-17-0768","article-title":"Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition","volume":"77","author":"Yaeger","year":"2017","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"V109","DOI":"10.1093\/annonc\/mdy149.026","article-title":"BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer","volume":"29","author":"Cuyle","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAFV600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1158\/1078-0432.CCR-11-1446","article-title":"Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents","volume":"19","author":"Mao","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.18632\/oncotarget.2602","article-title":"Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma","volume":"5","author":"Spagnolo","year":"2014","journal-title":"Oncotarget"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12935-017-0457-z","article-title":"Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells","volume":"17","author":"Notarangelo","year":"2017","journal-title":"Cancer Cell Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.celrep.2018.10.049","article-title":"BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association","volume":"25","author":"Vido","year":"2018","journal-title":"Cell Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-17-1124","article-title":"BRAF Gene Copy Number and Mutant Allele Frequency Correlate With Time to Progression in Metastatic Melanoma Patients Treated With MAPK Inhibitors","volume":"17","author":"Stagni","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/s41467-019-09438-w","article-title":"MEK1\/2 Inhibitor Withdrawal Reverses Acquired Resistance Driven by BRAF V600E Amplification Whereas KRAS G13D Amplification Promotes EMT-chemoresistance","volume":"10","author":"Sale","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.lfs.2018.04.050","article-title":"CXCR4 overexpression is correlated with poor prognosis in colorectal cancer","volume":"208","author":"Xu","year":"2018","journal-title":"Life Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13046-018-1014-x","article-title":"CXCL12\/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p","volume":"38","author":"Yu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/1940-6207.CAPR-14-0444","article-title":"TFF2-CXCR4 axis is associated with BRAF V600E colon cancer","volume":"8","author":"Gala","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Ottaiano, A., Scala, S., Normanno, N., Botti, G., Tatangelo, F., Di Mauro, A., Capozzi, M., Facchini, S., Tafuto, S., and Nasti, G. (2020). Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients. Appl. Immunohistochem. Mol. Morphol.","DOI":"10.1097\/PAI.0000000000000828"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1200\/JCO.2005.07.078","article-title":"Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival","volume":"23","author":"Kim","year":"2005","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1571\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:38:48Z","timestamp":1760175528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,14]]},"references-count":82,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061571"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061571","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,14]]}}}